S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage IIIB or stage IV breast cancer in remission.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer |
Drug: recombinant modified vaccinia Ankara-5T4 vaccine Procedure: adjuvant therapy Procedure: recombinant viral vaccine therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer |
| Enrollment: | 0 |
OBJECTIVES:
- Determine the feasibility of conducting a live viral vaccine trial using adjuvant recombinant modified vaccinia Ankara-5T4 vaccine (TroVax®) in patients with stage IIIB-IV breast cancer in remission.
- Determine the progression-free survival of patients treated with this vaccine.
- Determine the 5T4-specific T-cell immune response in patients treated with this vaccine.
- Determine the toxicity of this vaccine in these patients.
- Determine the level of 5T4-specific antibody response in patients treated with this vaccine.
- Correlate, preliminarily, immune response with 3- and 12-month progression-free survival of patients treated with this vaccine.
- Correlate tumor 5T4 expression with overall survival and progression-free survival of patients treated with this vaccine.
- Correlate tumor infiltrating lymphocyte and CD1a-positive dendritic cell density with development of 5T4-specific T-cell immunity in patients treated with this vaccine.
OUTLINE: This is a multicenter study.
Patients receive recombinant modified vaccinia Ankara-5T4 vaccine (TroVax®) intramuscularly once a month in months 1-3. Patients then receive booster vaccinations once in months 6, 9, and 12. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study within 2 years.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed breast cancer
Stage IIIB-IV disease
- Patients with stage IV disease must have metastasis to the bone only AND documentation of negative or improved bone scan showing evidence of recalcification by plain film x-ray OR MRI showing normalization of marrow signal
In remission (no evidence of disease)
- Must have completed appropriate treatment (e.g., radiotherapy and chemotherapy) for primary disease
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Not specified
Menopausal status
- Not specified
Performance status
- Zubrod 0-2
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- No known history of hepatitis B or C
Renal
- Not specified
Immunologic
- No known HIV positivity
- No known history of immune-deficiency disorder
- No history of allergic reaction to prior vaccinia vaccinations
- No autoimmune disease requiring concurrent treatment
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Concurrent trastuzumab (Herceptin®) allowed provided it is not part of treatment on another clinical trial
Chemotherapy
- See Disease Characteristics
- At least 28 days since prior cytotoxic chemotherapy
Endocrine therapy
- At least 28 days since prior steroid therapy
- Concurrent hormonal therapy allowed provided it is not part of treatment on another clinical trial
Radiotherapy
- See Disease Characteristics
- At least 28 days since prior radiotherapy
Surgery
- Not specified
Other
At least 28 days since prior and no concurrent treatment on another clinical trial
- Patients enrolled in a SWOG phase III metastatic trial (e.g.,SWOG-S0226 or SWOG-S0347) who have achieved complete remission but not yet progressed are not eligible
- Patients enrolled in a SWOG phase II metastatic trial or phase II/III adjuvant or neoadjuvant trial (e.g., SWOG-S0012, SWOG-S0215, SWOG-S0221, SWOG-S0338, or SWOG-S0430) who have achieved complete remission/no evidence of disease status and are no longer receiving study treatment are eligible
- Concurrent bisphosphonates allowed provided it is not part of treatment on another clinical trial
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00227474 History of Changes |
| Other Study ID Numbers: | CDR0000441167, S0348, U10CA032102 |
| Study First Received: | September 26, 2005 |
| Last Updated: | January 23, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Southwest Oncology Group:
|
stage IIIB breast cancer stage IIIC breast cancer stage IV breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on May 19, 2013